The New Economics of Employer-Sponsored Healthcare

For decades, employer-sponsored health insurance has been treated as a relatively stable part of compensation: a valuable benefit that helps companies recruit workers and gives employees access to the U.S. healthcare system. That assumption is becoming harder to sustain.

Healthcare costs are now forcing employers to make decisions that extend well beyond the benefits department. Premiums, medical claims and prescription spending increasingly compete with wages, hiring, capital investment and other corporate priorities.

The pressure is particularly visible in the outlook for 2026. Mercer estimates that the average cost of employer health benefits will rise 6.5% in 2026, even after employers account for planned cost-reduction measures. Without those changes, the increase would have been close to 9%.

Business Group on Health's employer survey points to an even higher median healthcare cost trend of 9% before plan-design changes, falling to 7.6% after those changes. The two estimates differ because they use different survey populations and methodologies, but both point to sustained pressure.

The economics of employee benefits are therefore changing. Healthcare is no longer simply an employee perk that companies budget for. It is increasingly a variable operating cost with implications for compensation, workforce strategy and competitiveness.

From benefit to balance-sheet consideration

The scale of employer-sponsored insurance makes this important beyond individual companies. KFF estimates that employer-sponsored coverage reached 165.6 million people under age 65 in March 2025, making it the largest source of health coverage for Americans in that age group.

The cost of that coverage has also continued to rise. In 2025, the average annual premium for family coverage reached $26,993, up 6% from the previous year. Workers contributed an average of $6,850, with employers paying the remainder.

For companies, the economic calculation is complicated. Cutting benefits can reduce expenses, but generous healthcare coverage is also part of total compensation. Reducing it too aggressively can make recruitment and retention more difficult, particularly in industries competing for specialized workers.

The result is a familiar corporate trade-off: employers want to control costs without undermining the value of the benefits that help them attract and retain employees.

Why the underlying costs are proving difficult to contain

Healthcare inflation is not being driven by one factor.

Medical prices remain important, but utilization is equally significant. Employers are seeing greater demand for services associated with chronic conditions, mental health, specialty treatments and complex diseases. Business Group on Health reported that both unit costs and utilization were contributing to higher spending.

Pharmacy spending has become another major pressure point. Business Group on Health reported that pharmacy accounted for 24% of employer healthcare spending in 2024 and that employers surveyed anticipated pharmacy costs rising by roughly 11% to 12% around 2026.

The pharmaceutical pipeline creates a structural challenge. New treatments can improve outcomes while also introducing substantially higher costs. GLP-1 medicines for obesity are one prominent example, but employers are also dealing with expensive cancer therapies and emerging cell and gene treatments.

Cancer illustrates the broader problem particularly clearly. For the fourth consecutive year, Business Group on Health's survey identified cancer as the leading condition driving employer healthcare costs. Eighty-eight percent of surveyed employers listed it among their top three cost drivers in 2025.

That does not mean every cancer case produces extraordinary costs. It does mean that increasing prevalence and expensive treatment options can have a disproportionate effect on employer-sponsored plans, particularly among large self-funded companies.

The burden is moving through the workforce

Employers have several ways to respond, but none is costless.

One approach is to absorb the increase. This protects workers from higher out-of-pocket expenses but leaves less money available for other corporate priorities.

Another is to shift some costs to employees through higher deductibles, copayments or premium contributions. Mercer reported in June 2026 that 48% of large employers expected to make changes to medical plans in 2027 that would increase employees' out-of-pocket costs.

That strategy can protect corporate budgets, but it changes the economics for workers. A nominally generous insurance plan can become less affordable if deductibles and other cost-sharing requirements rise faster than household incomes.

It can also create an unintended economic effect. When workers face higher costs at the point of care, some may delay treatment or avoid services altogether. In the short term, that can reduce claims. In the longer term, untreated conditions can become more expensive and potentially affect productivity and workforce participation.

Employers are consequently experimenting with alternatives rather than relying solely on cost shifting. Mercer found that nearly one-third of large employers either offer or plan to offer non-traditional medical plans in 2027, while another 38% are considering them. These include high-performance networks and variable-copay designs intended to steer workers toward lower-cost or higher-value care.

A more strategic role for employers

The next phase of employer healthcare is likely to focus less on simply paying for treatment and more on influencing where, when and how care is delivered.

Employers are increasingly looking at provider quality, negotiated prices, pharmacy-benefit arrangements, preventive care and specialized treatment networks. Business Group on Health found that 82% of surveyed employers viewed steering employees toward higher-quality sites of care as an action that could meaningfully improve healthcare quality, while the same proportion highlighted better quality transparency.

Cancer care is already producing this shift. About half of surveyed employers planned to offer a cancer center of excellence in 2026, with another 23% considering such programs by 2028. The objective is not simply to spend less, but to direct patients toward care that employers believe can deliver better outcomes for the money spent.

That distinction matters. Cost containment that reduces access can create different problems, whereas strategies based on better treatment decisions may reduce unnecessary spending without simply transferring the bill to workers.

The next test

The central question for employers is becoming less about whether healthcare costs will rise and more about how much of that increase they can manage without damaging the value of the benefit.

If medical and pharmacy inflation remain elevated, companies may continue redesigning plans, negotiating more aggressively with vendors and directing workers toward selected providers. If competition, policy changes or new payment models reduce underlying prices, some of that pressure could ease.

But the structural challenge will remain. Employer-sponsored insurance sits at the intersection of healthcare, labor markets and corporate finance. A rise in medical spending can become a higher insurance premium, which can become a larger compensation bill, a smaller wage increase, a higher employee deductible or a difficult hiring decision.

That makes healthcare more than an expense on the benefits ledger. For American companies, it is increasingly part of the economics of running a workforce—and therefore part of the economics of doing business itself.